A Phase 1/2 Study of CTX-712 in Leukemia and Myelodysplastic Syndromes

Recruiting Phase 1,Phase 2 NCT05732103

Study Description

A Study to Evaluate the Safety and Effectiveness of an Investigational Drug (CTX-712) in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Details

Registry ID:: NCT05732103
Conditions:: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase:: Phase 1,Phase 2
Target Enrollment:: 225 participants
Start Date:: April 25, 2023
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (8 sites)

Mayo Clinic Florida
Jacksonville, FloridaUnited States, United States
University of Virginia
Charlottesville, VirginiaUnited States, United States
The University of Rochester
Rochester, New YorkUnited States, United States
Northwestern University
Chicago, IllinoisUnited States, United States
The University of Texas MD Anderson Cancer Center
Houston, TexasUnited States, United States
Mayo Clinic Comprehensive Cancer Center
Rochester, MinnesotaUnited States, United States
Mayo Clinic Arizona
Phoenix, ArizonaUnited States, United States
Fred Hutchinson Cancer Center
Seattle, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →